Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Regul Toxicol Pharmacol. 2016 Jun;77:1-12. doi: 10.1016/j.yrtph.2016.02.003. Epub 2016 Feb 13.

Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: A case study using aromatic amine mutagenicity.

Author information

1
AstraZeneca, Mölndal, Sweden.
2
Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.
3
Toxicology Solutions, San Diego, CA, USA.
4
Leadscope, Columbus, OH, USA.
5
Bristol-Myers Squibb Co., New Brunswick, NJ, USA.
6
Genentech, South San Francisco, USA.
7
Janssen Research and Development, Beerse, Belgium.
8
GlaxoSmithKline, Ware, UK.
9
National Institute of Health Sciences, Tokyo, Japan.
10
Eli Lilly and Company, Indianapolis, IN, USA.
11
European Commission Joint Research Centre, Ispra, Italy.
12
Vertex, Boston, MA, USA.
13
Pfizer, Groton, CT, USA.
14
FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA.
15
Bayer HealthCare, Berlin, Germany.
16
Incyte Corporation, Wilmington, DE, USA.
17
AstraZeneca, Cheshire, England, UK.
18
Leadscope, Columbus, OH, USA. Electronic address: gmyatt@leadscope.com.

Abstract

Statistical-based and expert rule-based models built using public domain mutagenicity knowledge and data are routinely used for computational (Q)SAR assessments of pharmaceutical impurities in line with the approach recommended in the ICH M7 guideline. Knowledge from proprietary corporate mutagenicity databases could be used to increase the predictive performance for selected chemical classes as well as expand the applicability domain of these (Q)SAR models. This paper outlines a mechanism for sharing knowledge without the release of proprietary data. Primary aromatic amine mutagenicity was selected as a case study because this chemical class is often encountered in pharmaceutical impurity analysis and mutagenicity of aromatic amines is currently difficult to predict. As part of this analysis, a series of aromatic amine substructures were defined and the number of mutagenic and non-mutagenic examples for each chemical substructure calculated across a series of public and proprietary mutagenicity databases. This information was pooled across all sources to identify structural classes that activate or deactivate aromatic amine mutagenicity. This structure activity knowledge, in combination with newly released primary aromatic amine data, was incorporated into Leadscope's expert rule-based and statistical-based (Q)SAR models where increased predictive performance was demonstrated.

KEYWORDS:

(Q)SAR; Aromatic amines; ICH M7; Mutagenicity; Pharmaceutical impurities; SAR fingerprint

PMID:
26879463
DOI:
10.1016/j.yrtph.2016.02.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center